v3.22.2

Balance Sheet Account Details | 6 Months Ended
--- | ---
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Account Details | Balance Sheet Account Details Accounts Receivable
| June 30, 2022 |  |  | December 31, 2021
Accounts receivable, net: |  |  |  |
Accounts receivable, trade | $ | 5,314,000 |  |  |  | $ | 5,624,000 |
Less allowance for doubtful accounts | (463,000) |  |  |  | (690,000) |
| $ | 4,851,000 |  |  |  | $ | 4,934,000 |
Inventory The components of inventories are as follows:
| June 30, 2022 |  | December 31, 2021
Inventory: |  |  |
Raw materials | $ | 837,000 |  |  | $ | 745,000 |
Finished goods | 19,754,000 |  |  | 11,642,000 |
| $ | 20,591,000 |  |  | $ | 12,387,000 |
Intangible Assets Intangible assets that are subject to amortization consisted of the following for the periods presented:
|  | June 30, 2022 |  | December 31, 2021
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount
Trade name |  | $ | 1,630,000 |  |  | $ | (372,000) |  |  | $ | 1,258,000 |  |  | $ | 1,630,000 |  |  | $ | (210,000) |  |  | $ | 1,420,000 |
Customer relationships |  | 3,950,000 |  |  | (773,000) |  |  | 3,177,000 |  |  | 3,950,000 |  |  | (378,000) |  |  | 3,572,000 |
Developed technology |  | 22,800,000 |  |  | (3,230,000) |  |  | 19,570,000 |  |  | 22,800,000 |  |  | (950,000) |  |  | 21,850,000 |
Intangibles, net |  | $ | 28,380,000 |  |  | $ | (4,375,000) |  |  | $ | 24,005,000 |  |  | $ | 28,380,000 |  |  | $ | (1,538,000) |  |  | $ | 26,842,000 |
Accrued Expenses Accrued expenses consist of the following:
| June 30, 2022 |  | December 31, 2021
Compensation expenses | $ | 4,861,000 |  |  | $ | 4,529,000 |
Goods received not invoiced | 1,238,000 |  |  | 1,073,000 |
Customer deposits | 73,000 |  |  | 826,000 |
Taxes payable | 722,000 |  |  | 677,000 |
Insurance | — |  |  | 1,011,000 |
Professional fees and royalties | 368,000 |  |  | 288,000 |
Warranty liabilities | 175,000 |  |  | 175,000 |
Accrued clinical study fees | 169,000 |  |  | 1,000 |
Other | 154,000 |  |  | 1,114,000 |
Total | $ | 7,760,000 |  |  | $ | 9,694,000 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration